Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Argus Health
McKinsey
Moodys
Accenture
Cantor Fitzgerald
Fish and Richardson
Boehringer Ingelheim
QuintilesIMS
Healthtrust

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,442,830

« Back to Dashboard

Which drugs does patent 7,442,830 protect, and when does it expire?


Patent 7,442,830 protects NINLARO and is included in one NDA.

This patent has forty-nine patent family members in thirty-two countries.

Summary for Patent: 7,442,830

Title:Proteasome inhibitors
Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s): Olhava; Edward J. (Cambridge, MA), Danca; Mihaela Diana (Mendham, NJ)
Assignee: Millenium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:11/890,412
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-001Nov 20, 2015RXYesNo► Subscribe► SubscribeYY METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-002Nov 20, 2015RXYesNo► Subscribe► SubscribeYY METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► SubscribeYY METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,442,830

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,687,662Proteasome inhibitors► Subscribe
8,871,745Proteasome inhibitors► Subscribe
8,530,694Proteasome inhibitors► Subscribe
8,003,819Proteasome inhibitors► Subscribe
8,772,536Proteasome inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,442,830

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina067824► Subscribe
Australia2007357338► Subscribe
BrazilPI0721905► Subscribe
Canada2695082► Subscribe
Chile2008002159► Subscribe
China101772507► Subscribe
China102961387► Subscribe
China105837608► Subscribe
Cyprus1113386► Subscribe
Denmark2178888► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Queensland Health
Covington
Fuji
Baxter
Chubb
Farmers Insurance
McKesson
Johnson and Johnson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot